home / stock / crpof / crpof news


CRPOF News and Press, Ceapro Inc

Stock Information

Company Name: Ceapro Inc
Stock Symbol: CRPOF
Market: OTC
Website: ceapro.com

Menu

CRPOF CRPOF Quote CRPOF Short CRPOF News CRPOF Articles CRPOF Message Board
Get CRPOF Alerts

News, Short Squeeze, Breakout and More Instantly...

CRPOF - Aeterna Zentaris and Ceapro Complete Merger Transaction

TORONTO and EDMONTON, Alberta, June 03, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”) and Ceapro Inc. (TSX-V: CZO) (OTCQX: CRPOF) (“Ceapro”), two innovative biopharmaceutical development companies, ...

CRPOF - Ceapro GAAP EPS of -C$0.02, revenue of C$2.8M

2024-05-30 08:22:00 ET More on Ceapro Financial information for Ceapro Read the full article on Seeking Alpha For further details see: Ceapro GAAP EPS of -C$0.02, revenue of C$2.8M

CRPOF - Ceapro Inc. Reports Financial Results for First Quarter 2024 and Provides Corporate Update

– Q1 2024 marked by significant advancement of R&D projects focused on avenanthramide Phase 1-2a clinical study and the processing of yeast beta glucan along with the building of pilot scale units for PGX Technology – Q1 2024 sales of $2,800,000 vs $3,500,0...

CRPOF - Expected US Company Earnings on Thursday, May 23rd, 2024

Faraday Future Intelligent Electric Inc. (FFIE) is expected to report for Q1 2024 D-Market Electronic Services & Trading (HEPS) is expected to report for Q1 2024 Christian Dior SE ADR (CHDRY) is expected to report for Q1 2024 Check-Cap Ltd. (CHEK) is expected to report $-0.17 for ...

CRPOF - Ceapro Inc. Reports 2023 Financial Results and Operational Highlights

– 2023 marked by Ceapro’s achievement of key milestones and progress toward its next phase of growth – R&D activities focused on advancement of avenanthramide Phase 1-2a clinical study and the processing of yeast beta glucan along with the building of pi...

CRPOF - Ceapro Receives Final Court Approval for Merger with Aeterna Zentaris

TORONTO and EDMONTON, March 28, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (" Aeterna ") and Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“ Ceapro ”) are pleased to announce that the Court of King's Bench of Alberta has issued a final order approvin...

CRPOF - Aeterna Zentaris and Ceapro Merger Approved by Securityholders at Special Meetings

TORONTO and EDMONTON, Alberta, March 12, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“ Aeterna ”) and Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“ Ceapro ”) are pleased to announce that securityholders of both biopharmaceutical devel...

CRPOF - Leading Independent Proxy Advisory Firm ISS Recommends Aeterna Zentaris and Ceapro Securityholders Vote FOR the Arrangement Agreement to Approve the Merger of Equals to Create a Diversified Biopharmaceutical Company

ISS states in its Aeterna Zentaris FOR recommendation that “on balance, the deal has strong strategic merit, third party solicitation was unable to generate any other actionable proposals, and governance conflicts appear to have been reasonably managed.” ISS states in it...

CRPOF - Ceapro Provides Business Update on Progress of Ongoing Development Programs, Technology and Cosmeceutical Base Business

EDMONTON, Alberta, Feb. 23, 2024 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), today provided an update on its progress across its current business. On December 14, 2023, the Company announced it entered int...

CRPOF - Ceapro Inc. Announces the Mailing of Meeting Materials in Connection With the Special Meeting of Securityholders to Approve Merger With Aeterna Zentaris

EDMONTON, Alberta, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSXV: CZO) (OTCQX: CRPOF) (“ Ceapro ” or the “ Company ”) is pleased to announce that it has mailed and filed a management information circular dated February 9, 2024 and related meeting material...

Next 10